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First paragraph  
 
Somatic cells acquire mutations throughout the course of an individual’s life. Mutations 
occurring early in embryogenesis will often be present in a substantial proportion of, but not 
all, cells in the post-natal human and thus have particular characteristics and impact1. 
Depending upon their location in the genome and the proportion of cells they are present in, 
these mosaic mutations can cause a wide range of genetic disease syndromes2 and 
predispose to cancer3,4. They have a high chance of being transmitted to offspring as de novo 
germline mutations and, in principle, can provide insights into early human embryonic cell 
lineages and their contributions to adult tissues5. Although it is known that gross 
chromosomal abnormalities are remarkably common in early human embryos6 our 
understanding of early embryonic somatic mutations is very limited. Here, we use whole 
genome sequences of adult normal blood from 241 individuals to identify 163 early embryonic 
mutations. We estimate that approximately three base substitution mutations occur per cell 
per cell-doubling in early human embryogenesis and these are mainly attributable to two 
known mutational signatures7. We used the mutations to reconstruct developmental lineages 
of adult cells and demonstrate that the two daughter cells of many early embryonic cell 
doublings contribute asymmetrically to adult tissues at an approximately 2:1 ratio. This study 
therefore provides insights into the mutation rates, the mutational processes and the 
developmental outcomes of cell dynamics operative during early human embryogenesis. 
 
 3 
Main text 
Somatic point mutations of early embryonic derivation that are present in a substantial 
proportion of adult cells are detectable by standard DNA sequencing approaches. They can 
be distinguished from inherited single nucleotide polymorphisms (SNPs) as they will generally 
show lower variant allele fractions (VAFs). For example, early somatic mutations arising in 
one of the two daughter cells of the fertilized egg will show VAFs of ~25% in an adult tissue 
(Fig. 1a), compared to ~50% for inherited heterozygous polymorphisms, if the two cells have 
contributed equally to the adult tissue analysed8. Therefore, to identify early embryonic base 
substitutions, we analysed whole-genome sequences of blood samples from 279 individuals 
with breast cancer, in the first instance seeking mutations with VAFs ranging from 10% to 
35%. However, with sequencing coverage of these samples at a median of 32-fold 
(Supplementary Table 1) a substantial number (50,000-100,000) of inherited heterozygous 
SNPs would also be expected, by chance, to show VAFs less than 35% thus interfering with 
specific detection of early embryonic mutations. To address this problem, we examined the 
relationship of low VAF substitutions to nearby (<500bp distant) heterozygous germline 
SNPs. Early embryonic mutations will be found on just a fraction of the sequencing reads that 
also carry a particular allele of a nearby heterozygous germline polymorphism (Fig. 1b). By 
contrast, an inherited SNP that by chance has a low VAF will be found on all such reads. 
Given the presence of approximately two million heterozygous SNPs in an individual human 
genome, a significant number of low VAF base substitutions can be interrogated in this 
manner. After further filtering and subsequent experimental validation by ultrahigh-depth 
targeted sequencing (median read-depth=22,000x), we identified 605 somatic base 
substitutions with highly accurate VAF estimates that appeared to be present in only a 
proportion of adult blood cells (Methods). 
 
Mutations present in a subset of white blood cells can also reflect the presence of neoplastic 
clonal expansions arising from adult haematopoietic stem cells during the course of life9-11. 
However, blood samples in which neoplastic clones constitute a substantial proportion of the 
cells present will often display large numbers of low VAF mutations, because mutations 
present in the most recent common ancestor (MRCA) cell of the neoplastic clone have 
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usually been acquired over decades, rather than a few days for mutations of early embryonic 
origin (Extended Data Fig. 1). Indeed, the distribution of the number of mosaic mutations in 
the 279 samples indicated the presence of an outlier group of 31 samples harbouring more 
mutations (n≥5) than expected by chance, compatible with the presence of neoplastic clones 
in these samples (Fig. 1c). Several additional features support the proposition that the low 
VAF mutations in these blood samples were predominantly from neoplastic clones (Extended 
Data Fig. 1). These include: their absence from the breast cancers from the same individuals 
(Figs. 1c-1e); the frequent presence of known driver mutations for haematological 
neoplasms; the median age of individuals carrying these clones being twelve years higher 
than the rest of the cases (64 vs. 52 years old, respectively; P=0.00003; Fig. 1f) consistent 
with previous reports that these cryptic neoplasms are more common in older individuals9-11; 
and mutations in these samples showing highly similar VAFs to each other, consistent with 
their presence in the same clone (Extended Data Fig. 2). We removed 38 samples with 
evidence of neoplastic clones in the blood from further analyses (Methods). 
 
After application of all filters, we obtained 163 mosaic mutations from 241 individuals, the 
large majority of which are likely to have arisen during early human embryogenesis (Fig. 1g; 
Supplementary Table 2; Extended Data Fig. 3). To confirm that such mutations are 
genuinely mosaic, we sequenced multiple single white blood cells from one individual and 
showed that the mutation analysed was only present in a subset (Fig. 1h).  
 
Most mutations of early embryonic origin would be expected to be present in all normal 
tissues and not just in white blood cells. From 13 individuals in whom putative early 
embryonic mutations had been detected in blood, we examined normal breast (composed of 
cells of ectodermal and mesodermal origins) and lymph nodes (composed of cells of 
mesodermal origin) for the presence of the early embryonic mutations. Most of the mutations 
were found in the additional normal tissues examined, with VAFs indicative of being mosaic 
and correlating with those found in blood, thus supporting the early embryonic origin of the 
mutations and further reducing the likelihood that they are due to neoplastic clonal 
haematopoiesis (Fig. 1i). The VAFs of the early embryonic mutations were lower in normal 
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breast and lymph node than in blood (Fig. 1i). This may be because, even at such an early 
stage of embryogenesis, there already exist different potentials of individual ICM founder cells 
to contribute to adult blood and other tissues but we cannot exclude other explanations 
(Supplementary Discussion 1). 
 
In contrast to normal tissues, which are composed of multiple somatic cell clones, a breast 
cancer derives from a single somatic cell. Thus an early embryonic mutation would be 
expected either to be present in all cells of a breast cancer or in none, rather than in a 
proportion of cells as observed in blood and other normal tissues (although in practice the 
presence of contaminating non-cancer cells in the cancer sample has to be corrected for; 
Method). This was the pattern observed, with 37 mosaic mutations shared between the blood 
and the breast cancer from the same individuals, 105 non-shared and 21 uncertain, either 
due to a large deletion in the relevant region of the cancer genome (n=14) or statistical 
ambiguity (n=7) (Figs. 2a, 2b). The proportion of early embryonic mutations shared between 
the blood and the cancer is predicted to change according to the stage of early embryonic 
development at which the mutation occurred, with mutations acquired later being shared less 
often (Extended Data Fig. 4). Consistent with this expectation, embryonic mutations with 
lower VAFs in blood were shared less frequently with breast cancers (Fig. 2c).  
 
These patterns of sharing of low VAF mutations in blood (which is of mesodermal origin) with 
normal and neoplastic breast tissue (which is of ectodermal origin) supports a model in which 
the most recent common ancestor (MRCA) cell of adult blood cells is the fertilized egg (Fig 
2d; Supplementary Discussion 2), or is the MRCA cell of all/most somatic cells, rather than 
an alternative model of a single MRCA of the blood occurring at a later stage of 
embryogenesis with very restricted subsequent fate. 
 
The VAFs of the 163 validated early embryonic mutations in blood, which ranged from 45% to 
1%, provide insights into the early cellular dynamics of embryogenesis (Fig. 3a). If, in the 
large majority of embryos, the first two daughter cells of the MRCA cell of blood contributed 
equally to adult blood cells (symmetric cell doubling), a narrow 25% VAF peak would be 
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expected for mutations acquired at this stage. However, this peak was not observed 
indicating that asymmetric contributions are common.  
 
To explore the basis of this asymmetrical contribution systematically, we generated a series 
of models of cell genealogies in which different branches contributed unequally to adult blood. 
The asymmetry that best fitted the observed VAF distribution is an average, across embryos, 
~2:1 contribution of the first two daughter cells (cells I-1 and I-2; Fig. 3b, 3c). Moreover, this 
~2:1 asymmetric cell contribution extends to two cells at the second cell generation (cells II-1 
and II-2; Fig. 3b, 3c) and possibly to the third cell generation (Methods). The model with 
unequal contributions was clearly superior to a null model of symmetric cell doublings 
(P=1x10-40, likelihood ratio test, Fig. 3a, 3b). This frequent unequal contribution of the earliest 
human embryonic cells to adult somatic tissues is consistent with previous indications from 
studies of mouse development5,12-15. 
 
The biological mechanism(s) underlying these asymmetrical contributions are not well 
understood. One daughter cell and its progeny may contribute more than the other because 
they intrinsically have a lower death rate, a higher proliferation rate and/or a preference for 
contributing to embryonic compared to extra-embryonic tissues14-16. Indeed, studies in mice 
have shown that cells separated from 2-cell embryos have different intrinsic developmental 
potentials16,17. Alternatively, the stochastic consequences of a bottleneck in early embryo 
development could be the source of the asymmetry. In the early blastocyst stage human 
embryo, which is composed of 50-100 cells (blastomeres), only the minority of cells (<20) 
present in the inner cell mass (ICM) eventually contribute to adult somatic tissues18. Under a 
model in which a small number (<20) of ICM founder cells are selected at random from a 
blastocyst composed of many (>50) equivalent blastomeres and most of the founder cells 
contribute to the specific adult cell types, it is likely that the progeny of the first two cells will, 
in many embryos, be selected in unequal proportions, as recently observed in mouse19. 
Indeed, our simulations indicate that stochastic allocation of early human embryonic cells into 
the ICM results in levels of asymmetric contribution similar to those observed, without any 
intrinsic differences of early cells (Fig. 3d; Extended Data Fig 5; Methods). Assuming the 
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stochastic hypothesis is correct, our simulation estimates that the number of ICM founder 
cells is approximately 10. Further studies will be needed, however, to clarify the source of the 
observed asymmetry in the contribution of early cells of the embryo to adult tissues.  
 
Using the asymmetric cell-doubling model, we reconstructed the numbers of base 
substitutions present in each early embryonic cell. Taking into account the sensitivity of our 
low VAF mutation detection (Method; Extended Data Fig. 3e), approximately 14 
substitutions are present with VAF 10%-35% in the blood of a person and we estimated a rate 
of 2.8 substitution mutations per cell per cell-doubling (Fig. 4a; Supplementary Discussion 
3; 95% confidence interval 2.4-3.3) especially for the cell doublings at the first and second cell 
generations. A similar rate is obtained under a simple model without asymmetric contributions 
(Fig. 4a; Methods). This mutation rate per cell-doubling may not, however, directly equate to 
a rate per cell division because early embryonic development may involve cell loss, perhaps 
due to fatal chromosomal aberrations6, and thus a cell-doubling may entail more than a single 
cell division. If cell loss is common in the first few divisions of life, the mutation rate per cell 
per cell division will be lower than the estimated rate per cell per cell-doubling cited above. 
 
We then validated the early embryonic mutation rate using whole-genome sequences of 
bloods from three large families20 (Fig. 4b). We found seven substitution mutations in children 
that were not present in their parents and that had features described above of early 
embryonic mutations (Extended Data Fig. 6). Of these, four were on paternally derived and 
three on maternally derived chromosomes. We obtained a similar early embryonic mutation 
rate of 2.8 per cell per cell doubling (95% Poisson confidence interval 1.1-5.8; Fig. 4a). 
 
The mutational spectrum of early embryonic mutations was predominantly C>T (42.9%), T>C 
(25.1%) and C>A substitutions (16.6%) (substitutions are referred to by the pyrimidine of the 
mutated Watson-Crick base pair) and was similar to that of de novo germline mutations 
(Extended Data Fig. 7a). Somatic mutations are caused by a diverse array of mutational 
processes including exogenous and endogenous mutagenic exposures, DNA modification, 
DNA editing and DNA maintenance mechanisms7. Each mutational process imprints a distinct 
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signature of mutations onto genomes on which it has been operative. We have previously 
developed methods for extracting mutational signatures from human cancers7 (Fig. 4c) and 
have identified >30 different mutational signatures 
(http://cancer.sanger.ac.uk/cosmic/signatures). A combination of just two of these signatures, 
signatures 1 and 5, optimally accounts for the spectrum of early embryonic mutations, 
contributing 28% and 72% mutations, respectively (Fig. 4c). Signature 1 is thought to be due 
to spontaneous deamination of 5-methyl cytosine to thymine which results in C>T transitions 
primarily at CpG dinucleotides (Extended Data Fig. 7b). The mutational process underlying 
signature 5 is currently unknown. These two mutational signatures are found in almost all 
human cancers and the numbers of mutations associated with them exhibit strong positive 
correlations with age, suggesting that their underlying processes are endogenous and 
operate in most normal somatic cells at relatively constant rates throughout life21. 
Furthermore, signatures 1 and 5 appear to be the dominant mutational signatures contributing 
to human de novo germline mutations20,21. The current study therefore extends their domains 
of activity to early embryogenesis. We do not exclude the possibility that more mutational 
signatures, contributing smaller numbers of mutations, are operating in early embryogenesis, 
but a larger set of mutations will be necessary to identify them. 
 
A very small number of early post-zygotic mutations have been previously reported22-24. This 
study therefore provides the first large-scale identification of early embryonic mutations with 
accurate VAF information, and illustrates the use of such information in elucidating 
developmental processes. The study reveals an average ~2:1 asymmetry of early human 
embryonic cells in terms of their contributions to adult tissues, thus providing insights into the 
fates of cells at very early developmental stages. Our results have also allowed the first 
estimate of the mutation rate and the mutational signatures and processes underlying base 
substitutions in the early human embryo, which appear to be comparable to those in mouse 
embryogenesis5 and in adult somatic human tissues20,25,26. The early human embryonic 
mutation rate estimated here implies that, using similar methods to those introduced in mice 
previously5, reconstruction of cell lineage trees using somatic mutations should be possible in 
humans.  
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METHODS 
 
Samples and sequencing data 
For initial discovery of early embryonic mutations, we analyzed whole-genome sequencing 
data from 304 blood samples of breast cancer patients which were sequenced as normal 
controls for the ICGC (International Cancer Genome Consortium) breast cancer study27. 
Genomic DNA was extracted from bulk white-blood cells collected from fresh peripheral 
bloods. Matched breast cancer samples for all the individuals were also analysed in parallel. 
Of these, 25 samples with putative DNA contamination were removed (see below for more 
details), and 279 samples were used for the detection of early embryonic mutations (the 
sample information is available in Supplementary Table 1). For validating the mutation rates, 
we also used whole-genome sequencing data from 19 blood samples from 3 families20. For 
confirmation of early embryonic mutations in non-blood normal tissues, we extracted genomic 
DNA from FFPE (formalin-fixed and paraffin embedded) lymph nodes and normal breast 
tissue surgically resected during mastectomy procedures. The whole-genome sequencing 
data analysed in this study were generated using Illumina platforms (either Genome Analyzer 
or HiSeq 2000). Sequencing reads were aligned to human reference genome build 37 
(GRCh37) using the BWA alignment tool28. All PCR duplicate reads were removed.  
 
DNA contamination control 
We thoroughly checked for possible sources of DNA contamination: tumour-normal swap; 
matched tumour DNA contamination in blood; and cross-contamination with DNA from other 
individuals. Cases of tumour-normal sample swap were identified by examining the presence 
of genome-wide copy number variations in the putative normal samples. Cases of matched 
tumour DNA contamination were identified by examining the VAFs in the blood sequencing 
data for the somatic substitution variants identified in the matched cancer using CaVEMan 
software29 (available at https://github.com/cancerit/CaVEMan/). When the average VAF of 
cancer specific substitutions was more than 1% in a blood sample, we regarded the blood 
sample to be contaminated by a matched tumour DNA sample. Finally, for each sample, the 
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level of DNA cross-contamination with tissue from other individuals was estimated as 
described previously30.  
 
Variant calling 
VarScan2 software31 was used for initial early embryonic variant calling. Input vcf files were 
generated from whole-genome sequencing bam files using samtools32 mpileup with three 
options -q 20, -Q 20 and -B. Then VarScan2 somatic was applied to blood samples with 
matched tumour samples as reference. Three options were applied for the VarScan2 running, 
--min-reads2 4, --min-ave-qual 20, and --strand-filter. We selected substitution variants with 
VAFs ranging from 0.1 to 0.35 as putative early embryonic mutations. We removed putative 
mutations near germline indels (within 5bp), because these are mostly false positives due to 
mismapping. Putative mutations likely to be sequencing artifacts and/or germline 
polymorphisms were removed if the variants were also present in the unmatched blood 
samples analysed in this study, or were known germline polymorphisms with at least 1% 
population allele frequency identified from the 1000 Genomes Project (Nov.2013), or 
deposited in dbSNP (v138). We removed putative variants in segmental duplications, simple 
repeats, repetitive sequences (RepeatMasker) and homopolymer sequences in the human 
reference genome (downloaded from UCSC genome browser, http://genome.ucsc.edu/). 
  
Substitution phasing 
We phased the putative embryonic variants to heterozygous germline substitutions using 
sequences from whole-genome sequencing as described previously30,33. For more 
conservative phasing, we did not use sequences at the 4bp extremes of each read, where 
substitutions and indels are not well called. From blood whole-genome sequencing data, we 
classified the putative variants into 4 groups, ‘phasing not available’, ‘mixed pattern’, ‘no 
evidence of subclonality’ and ‘subclonal’ using criteria as follows:  
(1) Phasing not available: no available read covering both the mutation and the 
heterozygous SNP in the vicinity 
(2) Mixed pattern: the putative variant is present in both the bi-allelic haplotypes of 
heterozygote SNPs  
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(3) No evidence of subclonality: the putative variant is completely and exclusively 
present on one of the two haplotypes of heterozygote SNPs 
(4) Subclonal: the putative variant is present in a fraction of one of the two haplotypes of 
heterozygote SNPs. The variant is not present on the other haplotype. 
Putative mutations categorized other than subclonal were removed. For the subclonal 
mutations, we estimated the probability of false subclonality due to sequencing errors. For 
this calculation, we counted only informative reads, which were participating in the phasing: 
reads covering the putative mutation locus and one of the alleles of the inherited 
heterozygous SNP in which the early mutation is linked. 
𝑃𝑃𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 = �(𝑄𝑄1𝑖𝑖 + 𝑄𝑄2𝑖𝑖 −𝑉𝑉
𝑖𝑖
𝑄𝑄1𝑖𝑖 ∙ 𝑄𝑄2𝑖𝑖) + �(𝑄𝑄1𝑗𝑗 + 𝑄𝑄2𝑗𝑗 −𝑊𝑊
𝑗𝑗
𝑄𝑄1𝑗𝑗 ∙ 𝑄𝑄2𝑗𝑗) 
                                    −�(𝑄𝑄1𝑖𝑖 + 𝑄𝑄2𝑖𝑖 −𝑉𝑉
𝑖𝑖
𝑄𝑄1𝑖𝑖 ∙ 𝑄𝑄2𝑖𝑖) × �(𝑄𝑄1𝑗𝑗 + 𝑄𝑄2𝑗𝑗 −𝑊𝑊
𝑗𝑗
𝑄𝑄1𝑗𝑗 ∙ 𝑄𝑄2𝑗𝑗) 
Q1 and Q2 are sequencing error rates of the bases at the putative mutation and the 
heterozygote SNP loci, respectively; i represents each of the informative reads harboring the 
mutant base at the early embryonic mutation site; V is the total number of informative reads 
with the mutant base; likewise, j represents each of the informative reads harboring a wild-
type base at the early embryonic mutation site and W is the total number of such reads. 
When there was more than one heterozygous SNP site that was used for phasing, we 
calculated a string of phasing error rates (Perror) from every SNP site and multiplied them to 
obtain an overall phasing error rate. 
 
Copy number of mutation loci 
We removed any putative mutation if it was located in a region with copy number higher than 
two. We isolated potential copy number variation of each genome using both intra-sample 
and inter-sample methods. For the intra-sample method, we calculated the standard deviation 
of read-depth from all (~2 million) germline heterozygous SNP sites from every normal whole-
genome sequencing dataset. When the local coverage of an early embryonic mutation 
candidate was higher than the 95% percentile (i.e. local depth is greater than genome-wide 
mean WGS coverage + 1.645 x stdev; it is ~46x in typical 30x coverage sequencing) of the 
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sample, we considered the site was possibly duplicated thus removed from our further 
analyses (Extended Data Fig. 8a). For the inter-sample method, we clustered the normalized 
normal WGS read counts of a candidate region (from 1kb upstream of the mutation site to 
1kb downstream) from all the samples included in this study. If the normalized copy number 
of the target sample was either an outlier in the clustering or was two times higher than 
expected from genome-wide average, the mutation candidate was considered to locate in a 
germline copy number variant region and thus filtered out (Extended Data Fig. 8b, 8c). 
 
Mutations shared by the paired tumour tissue 
Then we investigated whether the early embryonic mutation candidates were also present in 
cells of the breast cancer from the same individual. This is not always straightforward 
because (1) whole-genome sequencing of cancer tissue generates a mixture of sequences 
from cancer and contaminating normal cells and (2) copy number changes are quite frequent 
in the cancer genome. Using the ASCAT algorithm34, based on analysis of the variant allele 
fraction for heterozygous germline SNPs for regions departing from diploidy in the tumour 
genome, we estimated the tumour cell fraction (‘f’ in the formula below), ploidy of cancer 
genome (‘p’) and local A (major) and B (minor) allele copy numbers (‘a’ and ‘b’, respectively). 
Each mutant allele was previously phased to either A or B allele nearby. Using these 
estimates, we built a model for the expected number of reads (N) supporting the mutant allele 
in paired-cancer genome sequencing in three different scenarios: 
 
I) The mutant allele is not shared (and approximate 95% binomial confidence interval), 
𝑁𝑁 = 𝐷𝐷𝐷𝐷0 , (95% 𝐶𝐶𝐶𝐶: 1.96�𝐷𝐷𝐷𝐷0(1 − 𝐷𝐷0) ) 
, D is the read-depth of the mutant site in matched cancer WGS sequencing and 
𝐷𝐷0 =  2(1 − 𝑓𝑓)𝜌𝜌 �(𝑎𝑎 + 𝑏𝑏)𝑓𝑓 + 2(1 − 𝑓𝑓)��    
, ρ is the expected VAF of the mutant allele. 
 
II) The mutant allele is phased to B allele (with 95% confidence interval), 
𝑁𝑁 =  𝐷𝐷𝐷𝐷1, (95% 𝐶𝐶𝐶𝐶: 1.96�𝐷𝐷𝐷𝐷1(1 − 𝐷𝐷1)) 
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,  𝐷𝐷1 =  (𝑓𝑓𝑏𝑏 + 2(1 − 𝑓𝑓)𝜌𝜌) �(𝑎𝑎 + 𝑏𝑏)𝑓𝑓 + 2(1 − 𝑓𝑓)��   
If nB = 0 we cannot differentiate scenario I and II (loss-of-mutant allele). 
III) The mutant allele is phased to A allele (with 95% confidence interval), 
𝑁𝑁 =  𝐷𝐷𝐷𝐷2, (95% 𝐶𝐶𝐶𝐶: 1.96�𝐷𝐷𝐷𝐷2(1 − 𝐷𝐷2)) 
, 𝐷𝐷2 =  (𝑓𝑓𝑎𝑎 + 2(1 − 𝑓𝑓)𝜌𝜌) �(𝑎𝑎 + 𝑏𝑏)𝑓𝑓 + 2(1 − 𝑓𝑓)��  
According to these models, we assigned our mutation to four groups: ‘non-shared’ (model I), 
‘shared’ (model II or III), ‘loss-of-mutant allele’ (when the mutant allele is phased to B allele 
and b is 0) and ‘uncertain’ (when more than 1 model could explain or no convincing ASCAT 
result is available for the sample).  
 
Visual inspection 
We visually inspected all the candidate embryonic mutations using the Integrative Genomic 
Viewer35 and JBrowse36. We confirmed that genomic regions with putative embryonic 
mutations were not in sequences with evidence of artifacts and thus that any putative 
mutation was supported by high quality sequencing reads.  Two examples of early embryonic 
mutations are shown in Figs. 2a and 2b. 
 
Validation by MiSeq amplicon sequencing 
We tried to validate all the putative early embryonic mutation sites. We designed 959 pairs of 
PCR primers (Supplementary Table 3) for 863 candidate early mutations to make amplicons 
for the putative mutation sites along with the nearby heterozygote SNPs used for phasing 
from the blood and paired-cancer DNA samples of the individual harboring the putative 
mutation. After clean-up using ExoSAP-IT (Affymetrix Inc., Santa Clara, CA, USA), all 
amplicons from blood and matched cancer tissues were separately pooled and sequenced by 
2 x 250bp MiSeq sequencing (Illumina Inc., San Diego, CA, USA) 2 runs per pool, expecting 
> 1000x coverage per amplicon. Because the read-depth is very high in amplicon 
sequencing, we could obtain a much more precise variant allele fraction of the putative 
embryonic mutation along with accurate phasing to the germline heterozygote substitution. 
The VAFs for germline heterozygote substitutions in non-repetitive genome regions showed a 
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clear peak at 0.5 (Extended Data Fig. 9a). To estimate the extent to which the amplification 
process biased the VAFs, we fitted a beta-binomial distribution with mean 0.5 and dispersion 
to the numbers of reads supporting both alleles in heterozygous SNPs (which have an 
expected VAF=0.5). This confirmed that the additional uncertainty introduced by 
amplifications was very small (θ = 223.88, overdispersion ρ = 1/(1+ θ) = 0.004). This 
estimate of the overdispersion was used in the maximum likelihood asymmetric models. The 
targeted amplicon sequencing showed high precision in the assessment of the VAF of a 
mutation (Extended Data Fig. 9b). The MiSeq validation experiment confirmed that the 
candidate mutations were not sequencing artifacts nor inherited mutations both from the 
resulting VAFs (ranged from 0.01 to < 0.5, mostly < 0.35) and from phasing to the local 
heterozygous SNP. From this validation study, we found that there is a clear linear 
relationship between phasing error rates (as calculated above) and validation success rate 
(Extended Data Fig. 10).  We could not create amplicons from some mutation candidates 
due to lack of DNA samples or unsuccessful PCR reactions. Finally, we rescued 14 early 
embryonic mutations because they are likely to be true on the basis of phasing error 
probability (Supplementary Table 2). 
 
Mutation validation using single cells 
From the blood of one individual (PD7344) we sorted 144 granulocytes. Genomic DNA of 
each single cell was extracted and whole-genome amplified using the REPLI-g Single Cell Kit 
(Qiagen Inc.) using the manufacturer’s protocol. Of the 144 single cells, 131 provided 
substantial amounts of WGA DNA. PCR amplicons were produced targeting the early 
embryonic substitutions in the sample (chr3:187268541 C>A). PCR reactions were successful 
from 118 WGA DNAs. After clean-up of the 118 PCR products, capillary sequencing was 
performed. Of these, 41 showed allelic dropout of the DNA haplotype on which the embryonic 
mutation was present (absence of the T allele of rs17726238) and thus were not further 
considered. Among the 77 informative amplicon sequencing results, 24 showed clear 
evidence of the embryonic substitutions as shown Fig 1h.  
 
Late somatic mutations due to clonal haematopoiesis 
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Age-related clonal haematopoiesis is quite common, and observed in more than 10% of 
persons older than 65 years old9-11. Like mutations that have occurred in the very early 
embryo, these late mutations appear to be subclonal (mosaic) in adult blood. However, such 
late mutations are rarely shared with the breast cancer sample from the same individual 
because the vast majority of them occurred after formation of the three germ layers, 
specifically in the mesodermal lineage. In addition, late clonal expansions in the blood 
invariably carry a large number of co-clonal mutations accumulated throughout life37, and so 
many subclonal mutations with similar VAFs are detected together in the blood sample. In this 
study, we found that each blood sample harbors a median of 1 validated phased subclonal 
mutation. According to their distribution (Fig. 1c), we regarded 31 samples with at least 5 
validated subclonal mutations as outlier samples, defined as deviating from the median value 
by more than twice the interquartile range. Consistent with the hypothetical presence of late 
clonal expansions in these outlier samples, the proportion of non-shared mutations abruptly 
increases from this point (Fig. 1c). Furthermore, we searched 73 cancer genes which have 
been reported to drive clonal haematopoiesis9-11 for low VAF somatic mutations (supported by 
at least 3 mismatches) and identified eight samples with mutations in DNMT3A, ASXL1, 
JAK2, PTPN11 and CBL genes. Of these, four samples were found among the 31 outlier 
samples. Conservatively, the remaining four samples were also classified as containing clonal 
haematopoiesis despite the small number of mutations found in them, and therefore removed 
from downstream analyses. Finally, we assessed whether mutation candidates obtained from 
each sample showed significantly similar VAFs to each other compared to the other samples, 
indicating that those mutations may be present in same blood clone, and thus filtered out 
three additional samples. Indeed, from the 38 filtered samples, we observe that mutations 
have more similar VAF to the other mutations in the same sample (calculated by 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉
𝑉𝑉𝑉𝑉𝑉𝑉�������
, 
where I represents each mutation in the sample) compared to the mutations in samples with 
2-4 mutations (Extended Data Fig. 2). As a result, out of the total 279 samples, we classify 
241 samples as having no evidence of clonal haematopoiesis, and therefore informative for 
detecting embryonic mutations.  
Finally, we assessed whether matched tumour sequences showed evidence of the mutant 
allele with significantly higher VAFs than background sequencing error rate levels (Extended 
 20 
Data Fig. 9c). This would be expected, because normal cells are always present in cancer 
samples and a fraction of the normal cells would carry the mutant allele if a mutation is truly 
embryonic origin. Fifteen candidate mutations, which were not found in the matched tumour 
samples, were removed through this step. After application of all filters, we identified 163 
likely early embryonic mutations from 241 samples. 
 
Asymmetry in early cell doublings 
In order to fit different lineage models to the VAF of embryonic mutations, we used a 
likelihood approach. If read counts were fully independent, allelic counts from each mutation 
could be modelled as being binomially distributed. However, to account for the overdispersion 
caused by the amplification process prior to library preparation, we assume allelic counts to 
be beta-binomially distributed. As shown above, we estimated the overdispersion parameter 
θ=223.9 (CI95%: 201-248). Over 98.7% of heterozygous SNPs had a VAF in the range 
[0.4,0.6] in the re-sequencing dataset (Extended Data Fig. 9a) 
 
If the first cell doubling gives rise to two daughter cells that contribute equal numbers of cells 
to the adult (or the adult blood population), the doubling is considered symmetrical. 
Otherwise, the doubling is considered asymmetrical, with one cell contributing a fraction α1 of 
the cells in the adult and the other cell 1-α1. Assuming that embryonic mutations are 
heterozygous, the expected VAF of a mutation occurring in branch 1 of the lineage is 0.5*α1 
and in branch 2 is 0.5*(1-α1). The same applies to any doubling in the lineage, with the two 
daughter cells contributing αn and 1-αn, relative to the contribution of the mother cell (n). This 
allows calculating the expected VAFs in the adult cell population for mutations occurring at 
each branch of the model lineage tree (vb). 
 
For each embryonic mutation, j, we observe the number of mutant reads (mj) and the total 
coverage at the site (cj). The likelihood of observing a given mutation under a particular 
lineage model requires integrating the likelihood of observing the mutation under each branch 
of the lineage, considering also the mutation rate at each branch and the sensitivity to 
mutations from each branch. In other words, the VAFs are fitted to a mixture model as 
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mutations could have occurred at any branch in the tree. The total log-likelihood of the model 
is the sum of the log-likelihoods from all mutations. 
 
 
 
Where N is the total number of mutations in the dataset (N=163), B is the total number of 
branches in the model and rb is the (relative) mutation rate of the branch. sb is the (relative) 
sensitivity to mutations from the branch, which is a function of the expected VAF of mutations 
from the branch (vb). Sensitivity as a function of VAF is calculated as described in the section 
below. 
 
Statistical comparison of models of increasing complexity 
In order to evaluate whether a lineage with one asymmetric doubling fits the data significantly 
better than a symmetric model, we obtained the maximum likelihood estimate for αn from 
each of the 15 doublings from the first 4 cell-generations while keeping all other doublings 
symmetrical. The best 1-asymmetric-rate model is tested against the symmetric model with a 
likelihood ratio test with 1 degree of freedom, and the p-value is subjected to Bonferroni 
multiple testing correction to account for the 15 models evaluated. This revealed that a 
lineage where the first doubling is asymmetric with α1≈0.61 fits the data much better than a 
symmetric model (LL0=-1444.4, LL1=-1366.3, P <10-16). 
 
In order to test models with additional asymmetric rates we used a heuristic approach. 
Instead of testing all possible combinations of asymmetric rates, we tested the impact of 
adding an extra asymmetric rate to the previous model (14 alternative models). The best 
model included asymmetry in the cell doubling of the dominant daughter cell in the first cell 
doubling (LL1=-1366.3, LL2=-1349.102, Bonferroni-corrected P=3.1e-08). The same 
approach was used to find a better model with three and four asymmetric doublings. The best 
model with three asymmetric doublings is only marginally better than the best model with two 
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asymmetric doublings (LL3=-1344.784, Bonferroni-corrected P=0.021). More complex models 
provided no significantly improved fits to the data. 
 
In order to evaluate whether other asymmetric lineages with two or three asymmetric rates 
could provide better fits, we exhaustively calculated the maximum-likelihood values of all 
possible lineages with two or three asymmetric doublings in the first four cell-generations. No 
model provided a better fit to the ones found by the heuristic approach. This analysis strongly 
supports a lineage with at least two asymmetric rates (first and second branches).  
 
The confidence intervals shown in Fig 3c were calculated by non-parametric bootstrapping 
(i.e. resampling the original data with replacement) followed by numerical search of the 
maximum likelihood values of the top seven rates in the lineage. 
 
Estimating the average mutation rate from asymmetric lineage models 
Assuming a given lineage model, a global estimate for the average mutation rate per genome 
per doubling in the early embryo can be obtained with the following equation: 
 
 
 
N is the total number of embryonic mutations detected (N=163), S is the number of samples 
studied (S=241) and sb is the sensitivity to detect a mutation from a particular branch of the 
lineage tree. Further, an approximate estimate of the average mutation rate at different cell 
generations could be obtained using an Expectation-Maximisation (EM) algorithm. These 
estimates may be more robust against possible contamination from neoplastic expansions at 
very low VAFs than the global estimate above. 
 
Assuming a particular lineage, the relative probability (expectation step) of a mutation (j) 
coming from one particular branch (b) is given by:   
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In the first iteration of the EM algorithm, the mutation rate (rj) of all branches is considered 
identical. The number of mutations estimated to come from each branch is then calculated as 
the sum of these probabilities across all mutations: 
 
 
 
Nb is then used to update the mutation rate per branch (maximisation step). And these two 
steps are iterated until convergence, obtaining an improved fit to the data and estimates of 
the mutation rates per branch. To constrain the parameters of the model, the rates of all 
branches from the same cell-generation are maintained identical during the EM algorithm. 
Confidence intervals were obtained by bootstrapping (400 replicates). Importantly, allowing 
the mutation rates of the first three cell-generations to vary freely with respect to the rest of 
the lineage (values shown in main text, Fig. 4a), does not significantly improve the fit of the 
model (LL=-1347.0 as opposed to LL2, p-val=0.24, 3 degrees of freedom). 
 
Simulation of sensitivity 
We estimated the sensitivity for early embryonic mutations from simulation studies. The 
sensitivity will be dependent on the target VAF (ρ) of early mutations. First, we randomly 
generated 1,000 in-silico embryonic mutations genome-wide. In-silico mutations within known 
gaps of the human reference genome were removed and replaced by newly generated 
mutations. Note that this means that sensitivity and so the mutation rates estimated in our 
study exclude mutations present in gaps, which approximately correspond to ten percent of 
the human genome. Next, under 21 different theoretical VAF (ρ; 0.016, 0.028, 0.031, 0.056, 
0.063, 0.083, 0.111, 0.125, 0.139, 0.167, 0.194, 0.222, 0.250, 0.278, 0.306, 0.333, 0.361, 
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0.389, 0.417, 0.444, 0.472) we queried how many of them could be detected on average from 
the whole-genome sequences of 241 samples. The same filtration steps for real mutation 
candidates were applied for the in-silico mutations: if mutations are found in 1000 Genomes 
Project dataset, dbSNP variation, segmental duplications, simple repeats, repetitive 
sequences by RepeatMasker, homopolymers, and potential copy number gain regions, we 
regarded these mutations as undetectable. Then, for each potentially detectable in-silico 
mutation, and under several given ρ, we calculated the fraction of mutations that could be 
successfully detected and successfully phased to at least one heterozygous SNP nearby in 
each individual WGS.   
𝑃𝑃(𝑜𝑜𝑏𝑏𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜|𝜌𝜌) =  𝑃𝑃(𝑜𝑜𝑜𝑜𝑑𝑑𝑜𝑜𝑑𝑑𝑑𝑑𝑉𝑉𝑜𝑜𝑑𝑑|𝜌𝜌) ∙ 𝑃𝑃(𝑝𝑝ℎ𝑎𝑎𝑜𝑜𝑉𝑉𝑑𝑑𝑎𝑎|𝜌𝜌) 
where P(detection|ρ) is the probability of a mutation having a sufficient number of reads 
supporting the mutant allele (at least 4, or the cutoff value in this study) and a VAF within the 
range considered in the discovery phase of this study (from 10% to 35%). Likewise, 
P(phasing|ρ) represents the probability of successful phasing a mutation to the heterozygous 
SNP nearby. We calculated P(detection|ρ) and P(phasing|ρ) as below: 
𝑃𝑃(𝑜𝑜𝑜𝑜𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑜𝑜𝑑𝑑|𝜌𝜌) = � �𝐷𝐷
𝑜𝑜
�𝜌𝜌𝑒𝑒(1 − 𝜌𝜌)(𝐷𝐷−𝑒𝑒)𝑒𝑒𝑒𝑒𝑟𝑟𝑟𝑟𝑟𝑟𝑒𝑒𝑟𝑟𝑟𝑟(0.35𝐷𝐷)
𝑒𝑒=max(4,𝑒𝑒𝑒𝑒𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟(0.1𝐷𝐷))  
𝑃𝑃(𝑝𝑝ℎ𝑎𝑎𝑜𝑜𝑉𝑉𝑑𝑑𝑎𝑎|𝜌𝜌) = 1 − � ((0.5 + 𝜌𝜌)𝑆𝑆𝑖𝑖 + (1 − 𝜌𝜌)𝑆𝑆𝑖𝑖 − 0.5𝑆𝑆𝑖𝑖)max (1,𝑁𝑁)
𝑖𝑖
 
where roundup () and roundoff() functions round to the higher or the closest integer number, 
respectively. D is the read-depth of each detectable in-silico mutation site, N represents the 
total number of heterozygous SNPs which are available for phasing, i is each of the 
heterozygote SNPs and Si is number of reads spanning both a mutation locus and the 
heterozygous SNP. For simplicity of simulation, we assumed all the bases have a good base 
quality (i.e. phred score >20). Finally, we added all probabilities, P(observed|ρ), obtained from 
an individual given ρ. When ρ is fixed, P(observed|ρ) correlates with read-depth of blood 
whole-genome sequencing, and the regression line was obtained using loess regression. We 
obtained our sensitivity estimates for the 21 different ρ values using this approach and a 
simulated coverage of 32-fold coverage (median coverage for 241 blood samples). For 
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example, 4.41% of the 1000 in-silico mutations with ρ=0.25 were detectable when whole-
genome sequencing coverage was 32x (Extended Data Fig. 3e). 
 
A stochastic model of embryoblast formation  
In the maximum likelihood fitting of lineage models described above, a single lineage tree 
was fitted to the data from multiple different individuals. The resulting lineage intends to be a 
merely descriptive representation of the average contribution of different cells across 
embryos. The model implicitly assumes that the same asymmetric lineage describes all 
patients and that the first divisions of the embryo follow a largely constant pattern across 
individuals. It remains unclear whether early embryonic development in viable embryos under 
physiological conditions follows a strict plan in humans or whether there is extensive variation 
between individuals, as observed in mouse19. In the presence of extensive variation in the 
early lineage across embryos, the asymmetry rates estimated using a constant lineage 
should be interpreted with caution. 
 
Interestingly, extensive asymmetry in the contribution of the first cells of the embryo to the 
adult cell pool can also emerge under more stochastic models of embryo development. As a 
proof-of-principle, here we show how a bottleneck in the pre-implantation embryo, in which 
only a randomly selected subset of cells contributes to the final somatic tissues, can give rise 
to extensive asymmetry in the contribution of the first few cells of the embryo to the adult cell 
pool, not dissimilar to the general patterns observed in this study. 
 
All final embryonic tissues are thought to derive from a fraction of cells in the blastocyst 
termed the inner cell mass (ICM), while the rest of the blastocyst (the trophoblast) will form 
the placenta and other extra-embryonic supporting tissues, and will not contribute to the adult 
cell pool. In mice this separation is thought to involve about 12 ICM cells gravitating at the 
center of the blastocyst at the 32-cell stage38. This imposes a significant bottleneck to the 
contribution of the first few cells in the embryo to the adult cell pool. Let us consider a simple 
bottleneck model where a completely random subset of l cells from the n-cell stage embryo 
are selected to form the adult cell pool. If there were m cells carrying an early somatic 
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mutation out of a total of n, the probability to subselecting k in a draw of l cells is given by the 
hypergeometric distribution. This is to be multiplied by the probability that m cells are mutated 
due to early germline mutations. Without a bottleneck, variant alleles would only be expected 
at powers of ½, with intensities following an 1/f power law due to the increase in the number 
of cells with every cell doubling. Hence the probability of selecting k mutated cells out of a 
total n cells is given by: 
 
P(k;l,n) = Σ0<= i <= 2n phyperg(k; l, m = 2n-2i, n=2i) × 2i/ const            (1)               
where const is a normalisation constant. Note that this distribution has support on VAF k/l, 
rather than 1/2i. The latter is approached in the limit that l = n, that is that all cells would 
propagate to the final somatic tissue (Extended Data Fig. 5a). The overall probability of 
observing mutations at a given VAF v is then to be multiplied by the sensitivity S(v) to detect 
mutation a given frequency, and the additional dispersion arising from detecting mutations on 
a finite number of x sequencing reads at a given coverage c, modeled by a beta-binomial 
sampling model, as described in the deterministic modeling used in the previous sections. 
 
p(x;l,n,c) = Σk P(k;l,n) × S(k/l) × pbetabin(x; prob = k/l; disp =ρ)/ const (2) 
 
, the dispersion ρ is inferred from heterozygous SNPs and taken to be θ=223.9, ρ = 1/(1+ θ). 
 
We may hence fit the likelihood (2) to the observed data, knowing the number of mutated 
reads x and coverage c for each patient, given the number of ICM cells l and cells n. The 
maximum likelihood is obtained for l=11 ICM cells separating after 6 generations, or n=64 
cells (Extended Data Fig. 5b), although there are many solutions with similar likelihood.  
 
From Eq. (2), an estimate of the overall histogram p(v) can be computed as the average over 
all data points p(v; l, n) = Σ i  p(xi = vci; l, n, ci) / N, where N = 163 is the number of 
observations. Using a Bayesian approach, assuming a uniform prior on the number of cell 
generations at which ICM commitment occurs ranging from 3 to 8, and similarly a uniform 
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prior on the number of ICM cells ranging from 5:32, allows for computing the posterior 
probability of the observed data as: 
 
p(v) = Σ l Σnp(v;l,n) × p(l) × p(n) (3) 
The result is shown in Extended Data Fig. 5c. 
 
This model shows how a simple random selection of a subset of the cells in the early embryo 
can lead to substantial asymmetries in the contribution of the first few cells in the embryo to 
the final adult cell pool. We note that this represents one extreme of possible combined 
deterministic and stochastic scenarios. It remains unclear to what extent viable embryos 
under physiological conditions follow a tightly predetermined developmental plan or whether 
largely stochastic processes dominate before the formation of the first structures in the 
blastocyst. The available data cannot distinguish between these models, but we anticipate 
that more detailed analyses of early embryonic somatic mutations could shed some light on 
this question. In particular, deterministic models predict that all individuals will share a very 
similar lineage pattern while stochastic models predict largely different early lineages among 
individuals. 
 
Family analyses  
Genomic DNA was extracted from peripheral blood of 19 individuals from three large families. 
We detected subclonal substitutions in 13 children using identical methods for the blood 
tissues of 241 breast cancer patients, i.e. DNA contamination control, variant calling, phasing 
to nearby heterozygous SNP, assessment of copy number of the mutation loci, and visual 
inspection as described above. We detected 7 early embryonic mutations (Extended Data 
Fig. 6), which were subclonal and not shared by the parents or any siblings, therefore these 
are highly likely to be post-zygotic mutations which occurred at the early embryonic stages of 
a specific child. 
 
We calculated the rate of early mutations from families (Rfamily) as below: 
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𝑅𝑅𝑟𝑟𝑓𝑓𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓
𝑅𝑅� = 𝑁𝑁𝑟𝑟𝑓𝑓𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓𝑆𝑆𝑟𝑟𝑓𝑓𝑓𝑓𝑖𝑖𝑓𝑓𝑓𝑓 ∙ 𝛼𝛼 𝑁𝑁
𝑆𝑆
�     
 
Where R is the overall average early mutation rate (2.8 mutations per cell per cell 
generation), N is the number of mutations (n=163) and S is the total sample size (n=241). 
Likewise, Nfamily is the number of mutations (n=7) identified from family data and Sfamily is the 
total number of children analysed (n=13). α is relative sensitivity of early mutations in family 
data, which must be less than 1 because sequencing coverage is ~7x coverage lower in 
families (25x) than the unrelated 241 blood samples (32x). The simulation of sensitivity 
(shown above) suggests that α is 0.796. A Poisson Exant test was used to calculate the 95% 
confidence interval of Rfamily. 
Detecting contributions of mutational signatures 
Mutational signatures were detected by refitting of previously identified and validated 
consensus signatures of mutational processes 
(http://cancer.sanger.ac.uk/cosmic/signatures). All possible combinations of at least seven 
mutational signatures were evaluated by minimizing the constrained linear function: 
min
𝐸𝐸𝐸𝐸𝑟𝑟𝑒𝑒𝐸𝐸𝑟𝑟𝑒𝑒𝑒𝑒𝐸𝐸𝑖𝑖≥0
||𝐷𝐷𝑜𝑜𝑁𝑁𝑜𝑜𝑜𝑜𝑜𝑜𝐷𝐷𝐷𝐷𝑑𝑑𝑎𝑎𝑑𝑑𝐷𝐷𝑜𝑜𝑑𝑑𝑜𝑜����������������������������������������⃗ −  ��𝑆𝑆𝐷𝐷𝑎𝑎𝑑𝑑𝑎𝑎𝑑𝑑𝐷𝐷𝑜𝑜𝑜𝑜𝚤𝚤�����������������������⃗ ∗ 𝐸𝐸𝐸𝐸𝑝𝑝𝑜𝑜𝑜𝑜𝐷𝐷𝑜𝑜𝑜𝑜𝑖𝑖�|| 𝑁𝑁
𝑖𝑖=1
 
Here, 𝐷𝐷𝑜𝑜𝑁𝑁𝑜𝑜𝑜𝑜𝑜𝑜𝐷𝐷𝐷𝐷𝑑𝑑𝑎𝑎𝑑𝑑𝐷𝐷𝑜𝑜𝑑𝑑𝑜𝑜����������������������������������������⃗  and 𝑆𝑆𝐷𝐷𝑎𝑎𝑑𝑑𝑎𝑎𝑑𝑑𝐷𝐷𝑜𝑜𝑜𝑜𝚤𝚤�����������������������⃗  represent vectors with 96 components 
corresponding to the six types of single nucleotide variants and their immediate sequencing 
context and 𝐸𝐸𝐸𝐸𝑝𝑝𝑜𝑜𝑜𝑜𝐷𝐷𝑜𝑜𝑜𝑜𝑖𝑖 is a nonnegative scalar reflecting the number of mutations contributed 
by this signature. 𝑁𝑁  reflects the number of signatures being re-fitted and all possible 
combinations of consensus mutational signatures for N between 1 and 7 were examined, 
resulting in 2,804,011 solutions. Model selection framework based on Akaike information 
criterion was applied to these solutions to select the optimal decomposition of mutational 
signatures. The analysis revealed that signature 1 and signature 5 best describe the set of 
embryonic mutations. Including any other mutational signature did not improve the 
explanation of the set of embryonic mutations. 
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Figure Legends 
 
Figure 1. Detection of somatic mutations acquired in early human embryos.  
(a) Phylogenetic tree of early embryonic cells and transmission of an early embryonic 
mutation. Each white-filled circle represents an embryonic cell. The diploid genome is 
represented by two black bars inside the white circles. An early embryonic mutation occurring 
in a cell at the 2-cell stage is represented by a red square.  
(b) Early embryonic mutations appear as somatic mosaicism in normal polyclonal tissue, for 
example, blood. The mutations are found on a subset of sequencing reads from bulk tissue. 
(c) Distribution of the numbers of early embryonic mutations per individual genome showing 
all samples (red bars), and the finally selected samples with no evidence of haematopoietic 
clonal expansions (blue bars). The proportion of non-shared mutations (not present in breast 
cancers) is represented by the green line. Error bars denote 95% confidence intervals 
(binomial test). 
(d-e) Early embryonic mutations are either absent from cancer cells (‘non-shared’; d) or are 
fully clonal mutations in the cancer cells (‘shared’; e) depending on their embryonic cellular 
origins. 
(f) The median age of individuals with evidence of neoplastic expansion in blood is 12 years 
higher than individuals without it. 
(g) 163 early embryonic mutations identified from 241 individuals are represented by dots. 
The 23 human chromosomes are shown in the outer layer (excluding chromosome Y). The 
vertical axis in the inner layer represents the VAF of the mutation. Sharing with cancer cells 
and the substitution types are represented by the shapes and colours of the dots. 
(h) Single cell genome sequencing shows that a fraction of blood cells harbor a mosaic 
mutation (PD7344b, chr3:187,268,541 C>A). 
(i) Early mutations are also found in non-blood normal tissues with VAFs indicative of being 
mosaic and correlating with those found in blood. 
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Figure 2. Early embryonic mutations identified from sequencing of adult blood tissues 
paired with matched tumour tissue sequencing. 
(a) An example of an early embryonic mutation not shared with cancer cells. In the blood of 
patient PD6416, a G>A mutation at chr8:5,161,217 (highlighted in yellow) is present with a 
VAF of ~14% from both whole-genome and high coverage targeted-amplicon sequencing. 
This suggests that ~28% of adult white blood cells harbour the mutation. Consistent with its 
somatic origin, the mutation is present on a subset of reads that include variant alleles of two 
nearby germline SNPs (rs7009390 and rs7009505). This mutation was absent in the breast 
cancer cells from the same patient. The minimal low VAF (2.6%) observed in the targeted 
amplicon sequencing of the tumour is consistent with normal cells contaminating the tumour 
sample. 
(b) An example of an early embryonic mutation shared with cancer cells. In the blood of 
patient PD7211, a G>A mutation at chr6:161,658,557 (highlighted in yellow) is present with a 
VAF of ~20% in blood suggesting that ~40% of blood cells have the mutation in their 
genomes. The mutation is present in the cancer sample with a VAF of 42.1% in targeted 
amplicon sequencing, consistent with its presence in all cancer cells and a contaminating 
population of non-neoplastic cells that lack the mutation. 
(c) The proportion of mutations shared between the blood and the cancer correlates with the 
VAF of mutations in blood (from 1st quartile (low VAF, later mutations) to 4th quartile (high 
VAF, earlier mutations)), consistent with expectations for early embryonic mutations. 
(d) The observed proportion of shared mutations (26%; red bar) indicates that the MRCA cell 
of blood is likely to be the same as the MRCA cell of many or all somatic tissues and/or the 
fertilized egg. The four blue bars show the expected proportions of mutations shared between 
the cancer and blood when there are 0, 1, 2, or 3 cell generation gaps respectively between 
the MRCA of the blood and the MRCA of the breast cancer (Extended Data Fig. 3). Binomial 
tests, * P < 0.01; ** P < 10-9; *** P < 10-15. 
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Figure 3. Asymmetric average contributions of early embryonic cells to adult somatic 
tissues. 
(a) The distribution of VAFs of 163 early embryonic mutations in blood. Light green bars, VAF 
estimated from targeted ultra-high depth amplicon sequencing; gray bars, VAF estimated 
from whole-genome sequencing when targeted amplicon sequencing was not possible. The 
expected VAF distributions (with adjustment for sensitivity of mutation detection) from 
symmetric (equal contributions) and best-fitting asymmetric cell doubling model (unequal 
contributions) are shown with black and red lines, respectively.  
(b) A contour plot showing the optimization of asymmetries in cell doublings. The horizontal 
axis and vertical axis present the asymmetry levels for the first and the second dominant cell 
doublings (cell doubling of MRCA and I-1 cells, respectively). Compared to the symmetric 
model (black arrow), the maximum likelihood asymmetric model (red arrow) provides a much 
better fit to the data (P=1x10-40, Likelihood Ratio Test).  
(c) Maximum likelihood estimates of the average contribution of different cells to the adult cell 
pool. The genealogy of early ancestral cells of adult blood cells is shown. The final 
contributions of each early cell to adult tissues are presented as pie graphs in which the red 
slices indicate the contributions to adult blood of each embryonic cell. These estimated 
asymmetric rates are population averages and could emerge through deterministic 
developmental plans or through stochastic processes. The asymmetries of each cell doubling 
are shown in blue (significantly asymmetric) or gray (the possibility of symmetric doubling is 
not excluded). 
(d) The relative contributions of the first four cells (cell II-1 (blue), II-2 (light blue), II-3 (orange) 
and II-4 (red)) to adult somatic cells under a stochastic bottleneck model, in which a small 
number of cells of the early embryo (x-axis) are randomly selected to form the ICM (see 
Methods). 
 
Figure 4. Rates and mutational signatures of somatic mutations in the early human 
embryo. 
(a) Estimates of early embryonic mutation rates. Mutation rates from 163 early embryonic 
mutations calculated from the best-fitting asymmetric model (top green panel). The overall 
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rate and rate estimates for each cell generation are shown with red and black dots, 
respectively. Broken lines represent 95% confidence intervals obtained by bootstrapping (see 
Methods). Equivalent mutation rates from the symmetric model (middle orange panel). 
Mutation rate estimates from 3 families (bottom blue panel). 
(b) Early embryonic mutations from whole-genome sequencing of 3 large families. Pedigrees 
are shown. Seven de novo, low VAF mosaic mutations were found in 13 children. Each 
mutation is shown with a number (index) inside the white rectangles or circles in the 
pedigrees. The maternal/paternal origins of the chromosomes of the mutations are shown in 
red (maternal) or blue (paternal). One of the mutations (#5) in family 569 is shown in more 
detail with an IGV image (highlighted in blue). Daughter 4 has a de novo subclonal C>T 
mutation (chr9:120,446,887) on the paternally transmitted chromosome 9. 
(c) The mutational spectrum for 163 early embryonic mutations is displayed according to the 
96 substitution classification defined by the substitution class and sequence context 
immediately 5’ and 3’ to the mutated base as described in a previous study7. The observed 
spectrum can be decomposed into just two mutational signatures (#1 and #5) that were 
identified previously7.  
 33 
Acknowledgements 
We thank Magdalena Zernicka-Goetz at Gurdon Institute, Kevin J. Dawson at Wellcome Trust 
Sanger Institute and Thomas Bleazard at University of Manchester for discussion and 
assistance with manuscript preparation. This work was supported by the Wellcome Trust. 
Y.S.J is supported by EMBO long-term fellowship (LTF 1203_2012). P.J.C. is a Wellcome 
Trust Senior Clinical Fellow. The ICGC Breast Cancer Consortium was supported by a grant 
from the European Union (BASIS) and the Wellcome Trust. For the family study, Generation 
Scotland received core support from the Chief Scientist Office of the Scottish Government 
Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006].   
 
Author Contributions 
M.R.S. designed and directed the project. Y.S.J. performed overall study with bioinformatics 
analyses for detection of early embryonic mutations. I.M. and M.G. performed statistical 
testing to confirm unequal contributions of early cells and early mutation rates. L.B.A. carried 
out mutational signature analyses. R.R. and M.E.H. designed and directed family studies. 
H.R.D., M.R., S.N.-Z. performed cancer genome analyses and provided conceptual advice. 
M.P., A.F., C.A., N.P., S.G., and S.O.’M carried out laboratory analyses. S.M. supported 
clinical data analysis and curation. A.B., H.S., M.v.d.V., B.K.T.T., C.C., A.T., N.T.U., L.J.v.V., 
J.W.M.M., S.C., S.K., P.N.S., S.R.L., J.E.E., A-L.B-D., A.R., A.M.T., A.V. provided clinical 
samples and commented on the manuscript. P.J.C. supervised overall analyses. Y.S.J., I.M., 
M.G., L.B.A. and M.R.S. wrote the paper. 
 
Author Information 
Whole-genome sequence data have been deposited in the European Genome-Phenome 
Archive (EGA; https://www.ebi.ac.uk/ega/home) under overarching accession number 
EGAS00001001178. The authors declare no competing financial interests. Correspondence 
and requests for materials should be addressed to M.R.S (mrs@sanger.ac.uk). 
 
 
 
 34 
   
 35 
